Canadian Medical Association Journal,
Journal Year:
2023,
Volume and Issue:
195(47), P. E1648 - E1650
Published: Dec. 3, 2023
[Voir
la
version
anglaise
de
l’article
ici:
www.cmaj.ca/lookup/doi/10.1503/cmaj.230808][1]
Points
clés
En
octobre
2018,
le
Canada
a
été
premier
pays
du
G-20
à
légaliser
consommation
et
vente
cannabis
des
fins
récréatives
pour
les
adultes[1][2].
Cette
légalisation
visait
Canadian Medical Association Journal,
Journal Year:
2023,
Volume and Issue:
195(39), P. E1351 - E1353
Published: Oct. 9, 2023
KEY
POINTS
In
October
2018,
Canada
was
the
first
G-20
nation
to
implement
legalization
of
nonmedical
cannabis
use
and
supply
for
adults.[1][1]
Cannabis
in
had
primary
objectives
improving
cannabis-related
public
health
safety;
reducing
youth
access
cannabis;
The Lancet Public Health,
Journal Year:
2025,
Volume and Issue:
10(2), P. e148 - e159
Published: Feb. 1, 2025
SummaryCannabis
consumption
is
legally
prohibited
in
most
countries
the
world.
Several
are
legalising
cannabis
for
adult
consumption.
It
important
to
monitor
public
health
effects
of
these
policy
changes.
In
this
paper,
we
summarise
evidence
date
on
legalisation
non-medical
use
Canada
and
USA.
We
describe
regulatory
models
legalisation,
changes
products
pricing,
illicit
market,
use,
cannabis-related
physical
mental
harms.
discuss
challenges
assessing
outcomes
emphasise
importance
continuous
rigorous
monitoring
adverse
inform
design
policies
regulations.
Indian Journal of Psychiatry,
Journal Year:
2025,
Volume and Issue:
67(3), P. 283 - 302
Published: March 1, 2025
Background:
Cannabis
has
been
associated
with
psychopathology
since
ancient
times,
but
controversies
continue
despite
important
advances
in
the
field.
This
article
is
fourth
one
our
decadal
series
of
review
articles
that
have
providing
an
update
snapshot
meandering
journey
research
findings
this
area.
Aims:
narrative
a
comprehensive
literature
search
over
past
10
years
aims
to
provide
and
current
understanding,
while
raising
unanswered
questions
for
future,
focusing
on
following
areas:
(a)
nosological
changes
cannabis-related
psychiatric
syndromes;
(b)
newer
category
synthetic
cannabinoids;
(c)
cannabis
withdrawal
syndrome);
(d)
psychosis;
(e)
mood
disorders;
(f)
suicidality;
(g)
prenatal
use
offspring;
(h)
effect
recent
liberal
policy
overhaul
control
certain
countries/areas
adverse
outcomes;
(i)
cognition;
(j)
cannabis,
psychopathology,
genetics.
Methods:
The
data
strategies
involved
combination
electronic
databases
manual
hand-searching
relevant
publications
cross-references
using
selected
terms.
primary
focused
Medline
PubMed
Central
extended
such
as
Google
Scholar,
PsychINFO,
Scopus,
Ovid
specific
sections.
Key
references
identified
through
searches
provided
additional
material.
Inclusion
criteria
spanned
studies
published
between
January
2014
June
2024,
more
emphasis
placed
(post-2020)
ensuring
historical
coverage.
Results:
aimed
be
comprehensive,
including
broad
range
without
strict
methodological
exclusions.
Strengths
limitations
cited
are
discussed
when
applicable,
maintaining
consistency
three
prior
reviews.
We
syndromes,
human
(rather
than
animal)
studies,
applied
basic)
research.
only
reference
not
entire
area
because
would
beyond
scope
article.
There
updates
all
areas
covered.
syndromal
entities
ICD-11,
which
also
includes
cannabinoids
first
time.
syndrome
better
characterized.
association
psychosis
robustly
established
especially
very
high-potency
vulnerable
populations,
particularly
young
people.
Work
progress
elucidating
causal
mechanisms.
links
disorders
well
suicidality
cognitive
impairment
characterized,
though
remain.
Recent
liberalizing
policies
produced
accidental
(with
deleterious
effects
offspring)
later
(mixed
findings,
documented
increase
emergency
visits
related
use).
will
require
active
monitoring
new
data.
Conclusion:
field
continues
collect
settle
some
old
questions,
address
view
wide
worldwide
its
implications
public
health.
International Journal of Drug Policy,
Journal Year:
2025,
Volume and Issue:
142, P. 104796 - 104796
Published: May 19, 2025
Several
jurisdictions
have
pursued
reforms
that
regulate
cannabis
production
and/or
sale
for
adult
(non-medical)
use.
Looking
at
outcomes
of
such
across
multiple
may
help
to
identify
are
inherent
non-criminal
supply,
as
well
provide
insight
into
the
specific
regulation
models.
We
identified
nine
indicators
policy
and
aggregated
them
three
domains
(social
outcomes,
in
use,
health-related
outcomes).
assessed
these
five
with
different
models
regulating
supply
(Netherlands,
Spain,
U.S.
states
legalized
cannabis,
Uruguay,
Canada).
used
a
three-level
systematic
literature
review,
prioritising
studies
quasi-experimental
design
(i.e.
comparative
longitudinal).
categorised
according
their
type
outcome
(increase,
decrease,
or
no
outcome).
Across
long-standing
recent
regimes,
our
review
common
outcomes:
decrease
cannabis-related
arrests,
an
increase
(but
not
adolescent)
healthcare
utilization
(not
traffic-related).
Negative
were
most
consistently
found
legalised
non-medicinal
use
(there
limitations
nuancing
states).
In
remaining
(the
Netherlands,
Canada,
Uruguay),
time-frame
was
limited,
on
certain
lacking.
Regulating
be
associated
benefits
social
area
potential
harms
regarding
public
health;
there
though
trade-offs
depending
choice
model.
Jurisdictions
attempt
mix
match
present
achieve
best
ratio
harms.
More
research
parameters
influencing
is
needed.
Drugs Education Prevention and Policy,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 7
Published: April 5, 2024
Background:
Cannabis
legalization
policy
is
increasingly
implemented
to
improve
public
health
and
safety
outcomes,
including
in
Canada
(since
2018).
Main
outcome
assessments
have
primarily
focused
on
categorical
(e.g.
pre-/post-)
reform
effects,
while
differential
regulation
frameworks
been
less
considered.
For
this,
provides
a
rich
ecology
where
provinces
diversely
define
many
parameters
under
the
federal
umbrella,
with
Alberta
Quebec
as
respectively
least
most
tightly
regulated
provincial
units.Methods:
Based
basic,
targeted
search,
we
identified
summarized
key
publicly
available,
cross-sectional
indicator
data
for
primary
socio-legal
post-legalization
outcomes
Quebec.Results:
Data
suggested
substantial
inter-provincial
differences
cannabis
use
among
adults
youth)
legal
sourcing
levels,
select
use-related
risks/harm
cannabis-impaired
driving,
cannabis-related
motor-vehicle-crashes).
Other
specific
poisonings,
home-cultivation)
showed
that
may
plausibly
relate
distinct
frameworks.Discussion:
While
possible
ecological
or
independent
effects
exist,
exploratory
suggest
different
regulatory
influence
legalization-related
and/or
outcomes.
Related
differentials
should
be
systematically
examined
causal
associations
regulations
towards
informing
evidence-based
development.
Addiction,
Journal Year:
2023,
Volume and Issue:
118(11), P. 2242 - 2243
Published: Aug. 6, 2023
We
appreciate
the
systematic
review
of
cannabis
legalization’s
impacts
in
Canada
by
Hall
et
al.
[1],
whose
content
overlaps
that
a
previous
[2].
Summaries
ever-growing
legalization
evidence
base
are
important
for
both
researchers
and
policymakers.
For
example,
Germany’s
Health
Ministry
asked
us
to
literature
inform
country’s
legislative
planning.
After
surveying
164
studies
from
Canada,
Uruguay
United
States
[3],
our
conclusions
were
similar
those
However,
we
wish
highlight
three
points
merit
greater
consideration
future
research.
First,
before
legalization,
use
had
already
been
increasing
years
[4].
Cannabis
prevalence
cannabis-related
emergency
department
visits
Ontario
rising
2018’s
[5,
6],
there
apparent
changes
alcohol
sales
after
medical
usage
expanded
2015
[7].
This
means
any
results
simple
before-and-after
comparisons
should
be
interpreted
with
great
caution.
therefore
recommend
post-legalization
account
pre-legalization
trends
appropriately
identified
control
groups
avoid
overstating
impacts.
could
conducted,
estimating
prior
predicting
out
then
comparing
them
actual
[8].
Secondly,
it
took
time
Canada’s
new
legal
market
establish
itself:
store
counts
grew
every
year
[9],
as
did
consumers’
willingness
disclose
[10].
researchers’
time-frames
greatly
affect
their
likelihood
detecting
effects
reviews
not
give
same
weight
of,
first
covering
3.
when
compared
fewer
than
2
data
more
2,
latter
provided
much
clearer
indications
increased
consumption
health
outcomes
[3].
other
place
emphasis
on
longer-term
post-treatment
study
designs.
Thirdly,
although
legalized
nation-wide,
meaningful
implementation
differences
among
its
13
provinces
territories
regarding
retailing
(e.g.
government-owned
versus
business),
public
smoking
allowed
banned)
products
allowed.
These
have
subsequently
seen
outcomes.
hospitalizations
poisonings
children
overall
but
increases
differed
according
degree
commercialization
product
types
sold
[11].
academics
policymakers,
interjurisdictional
at
least
interesting
national
averages.
pay
attention
this
heterogeneity
all
these
reasons,
is
treat
complex
process,
rather
an
instantaneous
binary
intervention.
Where
quality
permits,
increasingly
past
societal
trends,
ongoing
maturation
differences.
Researchers
also
complement
survey-based
methods,
such
analysis
work-place
toxicological
tests
[12]
or
wastewater
[13].
Jakob
Manthey:
Conceptualization
(lead);
writing—original
draft
writing—review
editing
(equal).
Michael
J.
Armstrong:
(supporting);
(lead).
Tobias
Hayer:
(supporting).
Daniel
T.
Myran:
Rosalie
Liccardo
Pacula:
Rosario
Queirolo:
Jürgen
Rehm:
Marielle
Wirth:
Writing—review
(support);
Frank
Zobel:
None.
Open
Access
funding
enabled
organized
Projekt
DEAL.
J.M.
has
worked
consultant
received
honoraria
agencies.
All
authors
do
declare
conflicts
interest.
Not
applicable.